Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:35 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 250 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Aged Healthy Volunteer Clear all

Conditions: Healthy
Interventions: Transdermal Microchannel Skin System, Sham device; Device
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 74 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Healthy Normal Volunteers
Interventions: Not listed
Lead sponsor: Astute Medical, Inc.; Industry
Eligibility: 21 Years and older
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2011
U.S. locations: 6
States / cities: Santa Ana, California • Las Vegas, Nevada • Rochester, New York + 3 more

Conditions: Lyme Disease
Interventions: VLA15, Placebo; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 7 Years and older
Enrollment: 1,712 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 19
States / cities: Bangor, Maine • Worcester, Massachusetts • Flemington, New Jersey + 13 more

Conditions: Cortisol Resistance, Negative Feedback, ACTH, Mineralcorticoid, Glucocorticoid
Interventions: Mifepristone, Placebo, Spironolactone, Combined, Dexamethasone; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years to 80 Years · Male only
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Healthy, Elderly
Interventions: PF-04447943, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 65 Years to 85 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Healthy Volunteers
Interventions: LY2605541; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Lyme Disease
Interventions: VLA15, Saline; Biological · Other
Lead sponsor: Pfizer; Industry
Eligibility: 5 Years and older
Enrollment: 12,546 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 82
States / cities: Essex, Connecticut • Ledyard Center, Connecticut • New London, Connecticut + 67 more

Conditions: Healthy Subjects
Interventions: Strength and Range of Motion; Other
Lead sponsor: Loma Linda University; Other
Eligibility: 15 Years to 22 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: Aged Healthy Volunteer
Interventions: Not listed
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 60 Years to 85 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Meningococcal Vaccine
Interventions: MenABCWY, Saline, rLP2086, MenACWY-CRM; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 10 Years to 25 Years
Enrollment: 1,610 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2022
U.S. locations: 60
States / cities: Birmingham, Alabama • Huntsville, Alabama • Fountain Hills, Arizona + 45 more

Conditions: Epstein-Barr Virus Infection
Interventions: mRNA-1195.1, mRNA-1195.2, mRNA-1189, Placebo, mRNA-1195; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 482 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 34
States / cities: Anniston, Alabama • Tucson, Arizona • Huntington Beach, California + 30 more

Conditions: Hepatic Impairment, Healthy
Interventions: ONO-2745 /CNS 7056; Drug
Lead sponsor: Ono Pharma USA Inc; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2013
U.S. locations: 3
States / cities: Anaheim, California • Orlando, Florida • South Miami, Florida

Conditions: Influenza, Pandemic Influenza
Interventions: H5N1 Influenza Vaccine, Whole virion, Vero cell-derived, Inactivated Influenza Vaccine, non-adjuvanted (reverse genetic reassortant/H5N1 hemagglutinin antigen); Biological
Lead sponsor: Alachua Government Services, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 422 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 6
States / cities: Wichita, Kansas • Lexington, Kentucky • Kansas City, Missouri + 3 more

Conditions: Age-Related Macular Degeneration, Diabetic Retinopathy, Von Hippel-Lindau Syndrome, Retinal Disease, Retinal Vein Occlusion
Interventions: Not listed
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 2 Years to 120 Years
Enrollment: 650 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2012
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Healthy Participants
Interventions: AZD5004; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 2
States / cities: Glendale, California • Baltimore, Maryland

Conditions: Healthy Volunteers, Norovirus
Interventions: NoV Vaccine; Biological
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 528 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 9
States / cities: Birmingham, Alabama • Fountain Hills, Arizona • Littleton, Colorado + 6 more

Conditions: Pharmacokinetic and Tolerability of Finafloxacin
Interventions: 400 mg finafloxacin (2 x 200 mg tablets); Drug
Lead sponsor: MerLion Pharmaceuticals GmbH; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Healthy
Interventions: Lasmiditan, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 2
States / cities: Daytona Beach, Florida • Evansville, Indiana

Conditions: Healthy Participants
Interventions: IVX-A12, Licensed RSV Vaccine; Biological
Lead sponsor: Icosavax, Inc.; Industry
Eligibility: 60 Years and older
Enrollment: 143 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 5
States / cities: Anaheim, California • Rolling Hills Estates, California • Hollywood, Florida + 2 more

Conditions: Healthy Elderly Volunteers
Interventions: Nicotinamide Riboside, Placebo; Dietary Supplement
Lead sponsor: Mayo Clinic; Other
Eligibility: 65 Years to 80 Years · Female only
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Healthy
Interventions: EMSAM (Selegiline Transdermal System) 6mg, EMSAM (Selegiline Transdermal System) 12mg; Drug
Lead sponsor: Somerset Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: Healthy Volunteers
Interventions: ASP1128, Placebo; Drug
Lead sponsor: Astellas Pharma Europe B.V.; Industry
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Glendale, California

Conditions: Vaccines, Meningococcal Vaccines
Interventions: rLP2086 + MCV4 + Tdap, MCV4 + Tdap + saline, rLP2086 + saline; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 10 Years to 12 Years
Enrollment: 2,648 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 117
States / cities: Birmingham, Alabama • Daphne, Alabama • Chandler, Arizona + 73 more

Conditions: Influenza, Healthy Volunteers
Interventions: Trivalent (TIV) messenger ribonucleic acid (mRNA) hemagglutinin (HA) Vaccine 1, TIV mRNA-neuraminidase (NA), TIV mRNA-HA Vaccine 2, Quadrivalent Influenza Standard Dose Vaccine, Quadrivalent Influenza Vaccine High Dose; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 50 Years and older
Enrollment: 1,162 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 21
States / cities: Birmingham, Alabama • Mobile, Alabama • Tempe, Arizona + 18 more

Search by objective public record fields.

Tolerability Study of the Application of a 3M Microstructure Transdermal System

A Normal Donor Sample Collection Study in Healthy Adults

A Study to Learn About the Safety, Tolerability, and Immunogenicity of a Fifth Dose of 6-Valent OspA-Based Lyme Disease Vaccine

Evaluation of Cortisol Resistance in Young Sedentary and Endurance-Trained Men

A Phase I, Multiple Dose Study of PF-04447943 in Healthy Elderly Volunteers

A Study of LY2605541 in Healthy Participants and in the Elderly

An Efficacy, Safety, Tolerability, Immunogenicity, and Lot-Consistency Clinical Trial of a 6-Valent OspA-Based Lyme Disease Vaccine (VLA15)

Shoulder Strength in Baseball Players

Dairy Intake and Brain Health in Aging

A Trial to Describe the Immunogenicity and Safety of 2 Doses of Bivalent rLP2086 (Trumenba) and a Pentavalent Meningococcal Vaccine in Healthy Subjects >=10 to <26 Years of Age.

A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants

An Open-label, Single-dose, Intravenous Administration Study of ONO-2745/CNS 7056 in Subjects With Chronic Hepatic Impairment

Phase 1 Study of a H5N1 Influenza Vaccine (Reverse Genetic Reassortant)

National Eye Institute Biorepository for Retinal Diseases

A Study to Investigate the Pharmacokinetics of Different Formulations and Safety of AZD5004 in Healthy Participants Aged 18 to 55 Years

Long-Term Immunogenicity of the Norovirus GI.1/GII.4 Bivalent Virus-like Particle (VLP) Vaccine (NoV Vaccine) in Adults

Effect of Age and Gender on the PK and Tolerability of Finafloxacin

A Study of Lasmiditan in Healthy Participants

A Study of IVX-A12 in Adults Participants

Effects of Vitamin B3 Derivative Nicotinamide Riboside (NR) in Bone, Skeletal Muscle and Metabolic Functions in Aging

PK Comparison of 6mg and 12mg EMSAM in Elderly vs. Non-Elderly

A Study of MA-0217 (ASP1128) in Healthy Adult Subjects and Healthy Elderly Subjects

A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to MCV4, Tdap and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 10 Through 12 Years of Age

A Study on the Safety and Immunogenicity of Hexavalent Influenza mRNA Vaccine in Adult Participants 50 Years of Age and Older